The application of NLRP3 inflammasome inhibition in Alzheimers disease therapeutics: Clinical benefits, applications, current limitations, and future development

Abstract

The severe dementia Alzheimers Disease (AD) has been a neurodegenerative disorder that has troubled many for years due to its difficulty in therapeutic development. Negative regulation of the expression and activation of the NLRP3 inflammasome situated in the hippocampus, entorhinal cortex, blood, and other brain-connected tissues have been reported to contribute to the decrease of pathology and effect of AD. This concise review focuses on the various applications, characteristics, efficacy, and potential of inhibitors of the NLRP3 inflammasome at different stages of the NLRP3 activation and expression pathway in addition to their various limitations that would be places of improvement in future pharmaceutical development. NLRP3 inflammasomes such as IC100 and MCC950 are still in a stage of development, with advantages of high specificity and a large range of function, but with a variety of limiting factors such as the lack of clinical trials and deciding studies, therefore causing a therapy with large potential to be still in a position needing great progress.